与多发性骨髓瘤风险相关的单核酸多态:系统性审查和元分析
Giovanna Gilioli da Costa Nunes1,2, Francisco Cezar Aquino de Moraes1,2, Aline Beatriz Carvalho de Almeida1,2
1Research Center of Oncology, Federal University of Pará Belém, Belém 66073-000, PA, Brazil.
International journal of molecular sciences
|April 17, 2025
概括
DNAH11,ULK4,DTNB和VDR的遗传变异与患多发性骨髓瘤的风险增加有关. 这些发现表明,可能有新的生物标志物用于早期评估这种血液癌症的风险.
科学领域:
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
背景情况:
- 多发性骨髓瘤是一种显著的造血性恶性瘤,具有相当大的发病率和死亡率.
- 准确的预后分层对于定制治疗策略至关重要.
- 遗传变化在多发性骨髓瘤的进展和治疗结果中起着至关重要的作用.
研究的目的:
- 研究特定遗传变异 (SNP) 与多发性骨髓瘤风险之间的关联.
- 为了确定潜在的遗传生物标志物来预测多发性骨髓瘤风险.
主要方法:
- 通过使用3421名多发性骨髓瘤患者和14720名对照患者的数据进行了全面的元分析.
- 数据来源于PubMed,科学网络和Scopus数据库.
- 聚合几率比率 (ORs) 和95%置信区间被计算出来,以评估SNP与多发性骨髓瘤风险之间的关联.
主要成果:
- 这项研究发现了与多发性骨髓瘤风险增加相关的几种遗传变异:DNAH11 rs4487645 A/C (OR=1.35),ULK4 rs1052501 A/G (OR=1.23),DTNB rs6746082 A/A (OR=1.10),以及VDR rs1544410 A/G (OR=1.87).
- ULK4 rs1052501 G/G基因型显示了增加风险的趋势 (OR=1.21,p=0.08).
- 统计分析证实了大多数已识别的SNP的显著关联 (p < 0.05).
结论:
- 基因DNAH11,ULK4,DTNB和VDR含有遗传变异,可能增加对多发性骨髓瘤的易感性.
- 这些已识别的遗传因素显示出多发性骨髓瘤风险分层的预测生物标志物具有前途.
- 进一步的研究可以探索这些遗传变异在多发性髓瘤发病过程中的功能影响.
更多相关视频
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
33.4K
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.3K
相关概念视频
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...